SAN DIEGO, CA – Dermata Therapeutics, Inc., a late-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today announced the issuance of a new patent in Japan for its DMT410 program for the treatment of hyperhidrosis. The patent, entitled “Compositions for the treatment of skin conditions,” (Japanese...
Latest News
Sitting in his favorite tiny red wooden chair, Teddy Christiansen peers out the window, smiling as he watches his older sister, Raelyn, play in the front yard. Before long, Teddy springs from the chair, itching to go outside himself. The bespectacled 33-month-old is everything he should be at his age:...
CARLSBAD, Calif. — Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced favorable data from a Phase 1 single- and multiple-ascending dose (SAD/MAD) trial of DT-168 in healthy volunteers, which will be presented on May 2, 2025 at Eyecelerator @ Park...
TOKYO, Japan & BASKING RIDGE, N.J. — The first patient has been dosed in the randomization phase of the DESTINY-Ovarian01 phase 3 trial evaluating ENHERTU® (trastuzumab deruxtecan) in combination with bevacizumab versus bevacizumab monotherapy as first-line maintenance therapy in patients with HER2 expressing (IHC 3+/2+/1+) advanced high-grade epithelial ovarian cancer...
Gainesville, Florida – Scientists have developed a saliva test that screens for breast cancer, which is showing promising results in experimental testing, according to a study published Tuesday. The new hand-held device detects breast cancer biomarkers from a tiny sample of spit, say researchers from the University of Florida and...
New York, NY – The Brain & Behavior Research Foundation (BBRF) is hosting a free webinar, “Developing Biological Markers to Improve Clinical Care in Autism” on Tuesday, February 13, 2024, at 2:00 pm ET. The presenter will be James McPartland, Ph.D., Harris Professor of Child Psychiatry and Psychology at Yale School...
Matsuyama, Japan – Multiple myeloma still appears to be an incurable hematological malignancy. One of the reasons is that myeloma cells can be heterogenous and acquire resistance after anti-myeloma treatment. Immunotherapy is an attractive strategy to target myeloma cells with drug resistance. The next-generation modality which can safely and effectively...
BOSTON, Mass. — Dewpoint Therapeutics Inc., a biotechnology company that translates the novel science of condensates into breakthrough therapeutics, today announced the filing of multiple patent applications covering novel compounds and their use in the potential treatment of amyotrophic lateral sclerosis (ALS). Composition of matter covered by these applications aims...
In patients with amyotrophic lateral sclerosis (ALS), treatment with dextromethorphan/quinidine (DM/Q) was not shown to prevent failure of noninvasive respiratory management and had no effect on long-term deterioration of bulbar function, according to the results of a prospective, case-cohort study published in Respiratory Medicine. Investigators sought to evaluate whether treatment with...
A drug currently FDA-approved for use in diabetes shows some protective effects in the brains of patients with relapsing remitting multiple sclerosis, researchers at the University of Illinois at Chicago College of Medicine report in a study currently available online in the Journal of Neuroimmunology. In a small, double-blinded clinical...